Myeloid Leukemia Clinical Trial
Official title:
Genome Wide SNP Array-based Approach to Detect Micro-cytogenetic Lesions and KIT Mutation to Improve Treatment Outcomes in Patients With Core-binding Factor Positive Acute Myeloid Leukemia
Core binding factor (CBF) positive acute myeloid leukemia (AML) consist of 15% of patients
in overall AML, expected to harbor a favorable prognosis. However, around a half of cases
relapses. Accordingly, more sophisticated classification in CBF positive AMLs is essential
to achieve further improvement in the treatment outcome. The current study is designed to
evaluate CBF positive AML patients with genome-wide SNP array and KIT mutation study in CBF
positive AML patients diagnosed at the Samsung Medical Center and Hwasun Chonnam National
University Hospital, Korea between 1994 and 2008.
1. Construction of the CBF positive AML patient cohort: clinical database establishment
(including treatment outcomes and prognosis) and extraction/storage of tumor cell DNAs
from marrow samples, then processing of Affymetrix SNP array 6.0.
2. Construction of prognostic predictive model using pharmacogenomics with the results of
genotypes and copy number variations (CNVs).
3. Detection of hidden microscopic cytogenetic lesions with SNP array technique, and
correlation with clinical outcomes in CBF positive AML.
4. Detection of KIT, FLT3/ITD, and NPM1 gene mutation and its correlation with clinical
outcomes in CBF positive AML.
The current study attempts to analyze genetic data of core binding factor (CBF) positive
acute myeloid leukemia (AML) using genome wide SNP array technique with tumor DNAs collected
at the time of diagnosis.
1. To detect microcytogenetic lesions and will analyze its prognostic significance
2. To analyze genome-wide genotypes and copy number variations (CNVs) using
pharmacogenetic approach and will construct a prognostic predictive model
3. To detect KIT, FLT3/ITD and NPM1 mutation and evaluate its prognostic significance. The
present study will establish individualized therapy for CBF positive AML, will provide
a basis for molecular marker guided clinical trial in CBF positive AML.
n/a
Observational Model: Case-Only, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Terminated |
NCT00543972 -
Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT00521664 -
A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups
|
Phase 3 | |
| Completed |
NCT05363488 -
Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland
|
||
| Completed |
NCT01380756 -
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
|
Phase 1 | |
| Recruiting |
NCT05031897 -
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant
|
Phase 2 | |
| Terminated |
NCT00126893 -
Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT03613727 -
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
|
Phase 2 | |
| Active, not recruiting |
NCT04714372 -
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT02763475 -
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
|
Phase 2 | |
| Terminated |
NCT01643603 -
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00497991 -
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
|
Phase 1 | |
| Not yet recruiting |
NCT05787951 -
Frequency and Risk Factors of Acute Myeloid Leukemia
|
||
| Completed |
NCT04628338 -
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
| Completed |
NCT02719821 -
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
|
N/A | |
| Active, not recruiting |
NCT00111345 -
Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents
|
Phase 2/Phase 3 | |
| Completed |
NCT00114764 -
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
|
Phase 2 | |
| Recruiting |
NCT05871008 -
Integrated Actionable Aging Assessment for Cancer Patients Pilot
|
N/A | |
| Recruiting |
NCT03638206 -
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05035706 -
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
|
Early Phase 1 |